Accessibility Menu
DiaSorin S.p.A. logo

DiaSorin S.p.A.(OTC) DSRLF

Market Cap$4.23BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)+357%
5 Year-54%
1 Year-19%
1 Month+11%
$85.47
-0.11%
-0.09Today
DiaSorin S.p.A. last closing stock price
MetricPriceDate
Last closeUSD 85.472026-08-10
DiaSorin S.p.A. stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+5.52%USD 81.002026-07-29
1 month+10.64%USD 77.252026-07-10
3 month+30.51%USD 65.492026-04-30
Year to date+14.99%USD 74.332025-12-26
1 year-18.8%USD 105.262025-06-20
3 year-6.66%USD 91.572023-07-10
5 year-54.3%USD 187.042021-08-11
Since inception+357.06%USD 18.702007-09-28

DiaSorin S.p.A. Financials at a Glance

Market Cap

$4.23BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€1.74B

Net Income (TTM)

€178.10M

EPS (TTM)

$3.08

P/E Ratio

26.50

Dividend

$1.51

Beta (Volatility)

2144.08 (High)

Price

$85.47

Volume

25

Open

$85.47

Previous Close

$85.47

Daily Range

$85.47 - $85.47

52-Week Range

$66.50 - $107.68

Estimated Earnings Date

Jul 31, 2026

DSRLF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About DiaSorin S.p.A.

DiaSorin S.p.A. is a leading player in the global diagnostics market, established in 1968 and headquartered in Saluggia, Italy. The company specializes in developing, producing, and distributing advanced immunodiagnostic and molecular diagnostic testing kits, serving a wide range of regions including Europe, Africa, and the Americas.

Products and Services
  • Immunodiagnostic testing kits through LIAISON platforms
  • Molecular diagnostic solutions via the LIAISON MDX platform
  • Strategic partnerships to enhance diagnostic capabilities
Growth Outlook
  • Revenue of €287 million in Q1 2026, indicating strong demand
  • Operating income margin of 19.5% reflects operational efficiency
  • Strategic alliances expected to drive future product innovations
Financial Highlights
  • Trailing twelve months (TTM) revenue of €1.2 billion, showcasing consistent growth
  • Net income of €38 million in Q1 2026, up from previous quarters
  • Dividend yield of 1.87% offers attractive returns for investors
DiaSorin S.p.A. has established itself as a significant entity in the healthcare sector, particularly in diagnostics. The company's diverse product offerings, including its LIAISON platforms, cater to a broad spectrum of diagnostic needs, enhancing its market presence. Recent financial performance indicates a robust growth trajectory, with a notable increase in revenue and net income in the latest quarter. The strategic partnerships with companies like QIAGEN and TTP further position DiaSorin to capitalize on emerging opportunities in the diagnostics field. With a solid foundation and a commitment to innovation, DiaSorin S.p.A. presents a compelling case for potential investors interested in the healthcare and diagnostics industry.
AI Generated • Jul 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

3,272

CEO

Carlo Rosa

Website

www.diasorin.com

Headquarters

Saluggia, VC 13040, IT

DSRLF Financials

Key Financial Metrics (TTM)

Gross Margin

64.48%

Operating Margin

15.82%

Net Income Margin

12.11%

Return on Equity

13.91%

Return on Capital

11.35%

Return on Assets

7.30%

Earnings Yield

3.77%

Dividend Yield

1.76%

Payout Ratio

30.88%

Stock Overview

Market Cap

$4.23BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

49.50M

Volume

25

Avg. Volume

115.048

Financials (TTM)

Gross Profit

€1.12B

Operating Income

€275.73M

EBITDA

€473.14M

Operating Cash Flow

€479.79M

Capital Expenditure

-€69.07M

Free Cash Flow

€410.72M

Cash & ST Invst.

€120.88M

Total Debt

€959.49M

DiaSorin S.p.A. Performance Analysis

DiaSorin S.p.A. annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 1,430,521,079-2.2%
20232023-12-31EUR 1,241,347,747-13.2%
20242024-12-31EUR 1,282,265,4283.3%
20252025-12-31EUR 1,348,712,7235.2%
DiaSorin S.p.A. sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-8.6%
Q42025-12-31105.5%
Q12026-03-31-50.1%
Q22026-06-30109.4%
DiaSorin S.p.A. annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 4.36-31.7%
20232023-12-31EUR 3.10-28.9%
20242024-12-31EUR 3.6216.9%
20252025-12-31EUR 3.12-13.9%
DiaSorin S.p.A. sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-89.7%
Q42025-12-31894.5%
Q12026-03-31-20.0%
Q22026-06-30108.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€601.10M

+96.3%

Gross Profit

€389.42M

+92.9%

Gross Margin

64.78%

N/A

Market Cap

$4.23BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.29M

N/A

Employees

3,272

N/A

Net Income

€83.87M

+76.9%

EBITDA

€134.80M

+42.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€120.88M

-30.7%

Total Debt

€959.49M

+24.7%

Accounts Receivable

€219.11M

+4.8%

Inventory

€369.01M

+12.5%

Long Term Debt

€789.18M

+48.5%

Short Term Debt

€170.31M

-28.4%

Return on Assets

7.30%

N/A

Return on Invested Capital

11.15%

N/A

Free Cash Flow

€76.05M

+57.5%

Operating Cash Flow

€109.07M

+47.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
FLMNFFielmann AG
$50.75+0.00%
CNVVYConvaTec Group Plc
$12.58+0.40%
GZPHFGuangzhou Baiyunshan Pharmaceutical Holdings Company Limited
$2.34+0.00%
GNGBYGetinge AB (publ)
$25.21+0.93%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.25+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.64-0.00%
ONDSOndas
$9.16+0.03%
INTCIntel
$103.10-0.01%

Questions About DSRLF

What is the current price of DiaSorin S.p.A.?

DiaSorin S.p.A. is trading at $85.47 per share.

What is the 52-week range for DiaSorin S.p.A.?

Over the past 52 weeks, DiaSorin S.p.A. has traded between $66.50 and $107.68.

How much debt does DiaSorin S.p.A. have?

As of the most recent reporting period, DiaSorin S.p.A. reported total debt of €929.55M.

How much cash does DiaSorin S.p.A. have on hand?

DiaSorin S.p.A. reported €194.72M in cash and cash equivalents in its most recent financial results.

What is DiaSorin S.p.A.’s dividend yield?

DiaSorin S.p.A. currently has a dividend yield of 1.76%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services